The study, which followed 195 patients recently diagnosed with multiple myeloma (MM), found that a negative PET/CT scan six months after diagnosis and induction therapy was significantly linked with improved survival.

The new equipment, which initially will be used to treat prostate and neuroendocrine tumors, is expected to be operational in July.

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested. 

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.

The research focused on a radiopharmaceutical that contains the isotope zirconium 89, which has a significantly longer half-life compared to gallium-68-labelled PSMA ligands.

For 47% of patients with long COVID symptoms, brain PET scans identified mild to moderate or severe hypometabolic patterns.